News und Analysen
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
GeNeuro and Verily Collaborate to Advance Long-COVID Research
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Q1 2023 Qualitative Update: Business Performance In Line With Full-Year Trajectory
Q1 2023 Qualitative Update: Business Performance In Line With
Full-Year Trajectory
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Lonza Completes Expansion of Conjugation Facility in Visp (CH)
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such
GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, die kausalen Faktoren zu stoppen, die das Fortschreiten von neurodegenerativen und
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple